

A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population

M. J. Young¹, A. J. M. Boulton¹, A. F. Macleod², D. R. R. Williams³ and P. H. Sonksen²

¹ University Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester,

² Department of Endocrinology and Chemical Pathology, St. Thomas' Hospital, London, and

³ Department of Community Medicine, Addenbrookes Hospital, Cambridge, UK

Summary. A cross-sectional multicentre study of randomly selected diabetic patients was performed using a standardised questionnaire and examination, to establish the prevalence of peripheral neuropathy in patients attending 118 hospital diabetes clinics in the UK. Vibration perception threshold was performed in two centres to compare with the clinical scoring systems. A total of 6487 diabetic patients were studied, 53.9% male, median age 59 years (range 18–90 years), 37.4% Type 1 (insulin-dependent) diabetes mellitus, with a median duration of diabetes 8 years (0–62 years). The overall prevalence of neuropathy was 28.5% (27.4–29.6%) (95% confidence interval) in this population. The prevalence in Type 1 diabetic patients was 22.7% (21.0–24.4%) and in Type 2 (non-insulin-dependent) diabetic patients it was 32.1% (30.6–33.6%). The prevalence of diabetic peripheral neuropathy increased with age, from 5% (3.1–6.9%) in the 20–29 year age group to 44.2% (41.1–47.3%) in the 70–79 year age group. Neuropathy was associated with

duration of diabetes, and was present in 20.8% (19.1–22.5%) of patients with diabetes duration less than 5 years and in 36.8% (34.9–38.7%) of those with diabetes duration greater than 10 years. Mean vibration perception threshold measured at the great toe was 21.1 ± 13.5 SD volts and correlated with the neuropathy disability score, $r = 0.8$ $p < 0.001$. In conclusion, diabetic peripheral neuropathy is a common complication associated with diabetes. It increases with both age and duration of diabetes, until it is present in more than 50% of Type 2 diabetic patients aged over 60 years. An increased awareness of the high prevalence of peripheral neuropathy, especially in older patients, should result in improved screening programmes in order to reduce the high incidence of neuropathic diabetic foot ulceration.

Key words: Diabetes Mellitus, peripheral neuropathy, epidemiology.

Estimates of the prevalence of diabetic peripheral neuropathy vary widely in the literature [1–11]. This apparent diversity is due to the relatively small size of these studies, to differences in the diagnostic criteria employed and to the different methods of patient selection. Whilst some authors have considered painful symptoms alone to be diagnostic [1], others have required signs of nerve dysfunction [2]. Dyck et al. [12] proposed that two of the following three criteria should be present for a diagnosis of peripheral neuropathy: signs of peripheral neuropathy, abnormalities of quantitative sensory testing or abnormal electrophysiological tests. Routine out-patient practice and mass screening requirements have led to the development of simpler scoring techniques for both symptoms [3, 13–15] and signs [4, 16]. The present survey used standardised questionnaires and examinations, based on these scoring systems. The aim of this study was to estimate the prevalence of peripheral neuropathy in the UK hospital clinic population and, by surveying a large number of patients, to study the relationship of prevalence to age and duration of diabetes.

Subjects and methods

One hundred and eighteen hospital diabetes clinics in the UK participated in the study. Each was requested to examine a total of 60 diabetic patients, attending routine clinic visits. Those centres with a register randomly selected 20 patients from each of three diabetes duration groups: less than 5 years, 5–10 years and more than 10 years. In those centres without a register patients were examined on a sample basis, usually every fourth or fifth patient, according to the size of the clinic. The data were collected simultaneously in all centres over a 2-month period. Demographic data and history of diabetes were recorded. Patients were designated as Type 2 (non-insulin-dependent) diabetic if they were not currently treated with insulin or were not started on insulin within 2 years after diagnosis. The characteristics of the patients examined are detailed in Table 1. The neuropathy disability score and neuropathy symptom score for each patient was derived as described in the following.

Neuropathy disability score (NDS): this was derived from examination of the ankle reflex, vibration, pin-prick and temperature (cold tuning fork) sensation at the great toe. The sensory modalities were scored as either present = 0 or reduced/absent = 1 for each side, and reflexes as normal = 0, present with reinforcement = 1 or absent = 2 per side. Thus the total maximum abnormal score was 10. A

Table 1. Patient characteristics

	Total number of patients	Male patients (%)	Median age (range)	Median duration of diabetes (range)
Type 1 diabetes	2414	1298 (53.7%)	45 (18–90) years	13 (0–62) years
Type 2 diabetes	3949	2129 (53.9%)	63 (19–90) years	6 (0–55) years
Unknown	124	71 (57.2%)		
Total	6487	3498 (53.9%)	59 (18–90) years	8 (0–62) years

Table 2. Diabetic neuropathy by region

Region	Total number of patients	Prevalence of diabetic neuropathy	Confidence intervals
Scotland	577	23.2	19.7–26.6
Yorkshire	562	31.3	27.5–35.1
N W Thames	538	23.4	19.8–27.0
N Western	508	28.3	24.4–32.2
Wales	497	26.2	22.3–30.1
Wessex	493	27.8	23.8–31.8
W Midlands	465	31.0	26.8–35.2
Trent	449	32.1	27.8–36.4
S E Thames	418	33.7	29.2–38.2
Northern	379	34.6	29.8–39.9
N E Thames	285	24.2	19.2–29.2
Oxford	277	34.3	28.7–39.9
S Western	220	30.0	23.9–36.0
Mersey	210	32.9	26.5–39.2
Ireland	184	22.3	16.3–28.3
S W Thames	181	27.0	26.5–39.2
E Anglian	152	21.7	15.1–28.2

score of 3–5 was regarded as evidence of mild neuropathic signs, 6–8 as moderate and a score of 9 or 10 as severe signs of neuropathy.

Neuropathy symptom score (NSS): patients were asked about their experience of pain or discomfort in the legs: if the patient described burning, numbness or tingling a score of 2 was assigned; fatigue, cramping or aching scored 1. The presence of symptoms in the feet was assigned a score of 2, the calves 1 and elsewhere a score of 0. Nocturnal exacerbation of symptoms scored 2 vs 1 for both day and night and 0 for daytime alone. A score of 1 was added if the symptoms had ever woken the patient from sleep. The patients were asked if any manoeuvre could reduce the symptoms: walking was assigned a score of 2, standing was 1 and sitting or lying down was 0. The maximum symptom score was 9. A symptom score of 3–4 was taken to imply mild symptoms, 5–6 moderate symptoms and 7–9 severe symptoms.

The minimum acceptable criteria for a diagnosis of peripheral neuropathy were: moderate signs with or without symptoms, or mild signs with moderate symptoms. Mild signs alone or with mild symptoms were not considered adequate to make a diagnosis of peripheral neuropathy.

In two centres (Manchester and St. Thomas') vibration perception threshold (Biothesiometer, Biomedical, Newbury, Ohio, USA) was measured at the great toe at the same time as the neuropathy disability score was derived. The Biothesiometer was balanced vertically on the pulp of the great toe to measure vibration perception and a mean of three readings was used to derive the value for each patient. A total of 98 patients were tested in this way in order to compare the clinical scoring systems with a standard test of neuropathy. All the Biothesiometers used in this study had been recently calibrated and tested for electrical safety.

Statistical analysis

Results were analysed using SAS Software (SAS Institute Inc, Cary, N. C., USA). Binomial proportions and confidence intervals were used to describe point and interval estimates of prevalence rates. The chi-squared test was used to compare crude prevalence rates between groups. Logistic regression was used to investigate independently significant factors for the presence of neuropathy. Correlation coefficients were calculated for age and duration of diabetes against prevalence of neuropathy in age/duration bands. Correlation coefficients were also calculated between the neuropathy disability and neuropathy symptom scores and vibration perception threshold.

Results

Prevalence data

The overall prevalence of diabetic peripheral neuropathy in this population was 28.5% (27.4–29.6%) (95% confidence intervals) and was similar in both male and female patients, 28.5% (27.0–30.0%) vs 28.5% (26.9–30.1%). There was no significant difference between University teaching hospital patients (29.4% [27.2–31.6%]) and district general hospital patients (28.3% [27.0–29.6%]) and no significant geographical trends were observed (Table 2). Type 2 diabetic patients had a higher overall prevalence of peripheral neuropathy than Type 1 diabetic patients, 32.1% (30.6–33.6%) and 22.7% (21.0–24.4%) respectively ($p < 0.001$), and this was reflected regardless of duration of diabetes (Fig. 1).

Diabetic peripheral neuropathy was also more prevalent with increasing duration of diabetes, from 20.8% (19.1–22.5%) in 2199 patients with diabetes duration of less than 5 years from diagnosis to 36.8% (34.9–38.7%) in 2532 patients with diabetes for more than 10 years (prevalence of peripheral neuropathy vs duration of diabetes $r = 0.18$ $p < 0.001$).

The prevalence of diabetic neuropathy increased with age from 5.0% (3.1–6.9%) in those patients aged 20–29 (502 patients), to 44.2% (41.1–47.3%) in those aged 70–79 (1012 patients) (Fig. 2). A correlation of $r = 0.994$ $p < 0.001$ was found between age and prevalence of neuropathy.

Logistic regression

A multiple logistic regression analysis of the prevalence of neuropathy was performed, using sex, age, type of diabetes and duration of diabetes as its predictors (Table 3). This confirmed that there was no difference in the prevalence of neuropathy between males and females. Age and duration of diabetes were significant independent predictors of prevalence (both $p < 0.001$). After correcting for age and duration differences, the excess of neuropathy in Type 2 diabetic patients persisted, with an odds ratio of 1.09, although this did not reach statistical significance.




Fig. 1. The prevalence of peripheral neuropathy in Type 1 (\square) and Type 2 ($+$) diabetic patients by duration of diabetes




Fig. 2. The prevalence of diabetic peripheral neuropathy by age

Vibration perception

The mean vibration perception threshold at the great toe was 21.1 ± 13.4 SD volts. A significant correlation was found between the mean vibration perception threshold of both toes and the neuropathy disability score, $r = 0.798$ $p < 0.001$. A weaker but significant correlation was found between vibration perception and the neuropathy symptom score, $r = 0.225$ $p = 0.026$.

Discussion

The wide variation in the reported rates of diabetic peripheral neuropathy can be explained on the basis of the different diagnostic criteria employed and study populations involved [1–11].

The diagnosis of peripheral sensorimotor neuropathy may be made on the basis of symptoms [3, 14, 15], signs [4, 16], quantitative sensory tests [17–19] or electrodiagnostic studies [20]. The consensus statement of the San Antonio conference on peripheral neuropathy recommended that an abnormality of one measure in each of these categories should be present for a diagnosis [20], which is clearly more practical in a research than in a routine clinical setting. Dyck et al. [12] proposed that abnormalities in two of three criteria were sufficient to diagnose peripheral sensorimotor neuropathy. The suggested criteria were signs of peripheral neuropathy, quantitative sensory testing and electrophysiological tests. However, because electrophysiological tests are not routinely

available in all centres, these criteria are not in use in everyday clinical practice. The neuropathy disability and symptom scores used in this study are modifications of those validated elsewhere [1, 3, 13–16]. A similar system comprising a short symptom assessment and brief clinical examination has proved workable in previous studies of up to 858 patients, correlating well with a standard neurological examination [3].

In this study vibration perception threshold [17], measured using a Biothesiometer was used to compare the clinical scoring systems with a quantitative sensory test of neuropathy, and a high correlation was found. This is in agreement with the findings of Franklin and co-workers [3], who compared their scoring system with the Optacon vibration perception threshold tester and found a similar correlation. The minimum diagnostic criteria employed in this study, moderate signs with or without symptoms, or moderate symptoms with at least mild signs of neuropathy, were chosen to ensure that absent ankle reflexes alone would not be enough to diagnose neuropathy and that symptomatic neuropathy could only be diagnosed if neurological signs were also present, thus avoiding the risk of overestimation by using mild transient symptoms alone [1]. The criteria were also chosen so that the mild symptoms and minor signs of neuropathy that normally occur in the general (non-diabetic) population with increasing age [21] would not distort the possible relationship between diabetic neuropathy and age.

The population surveyed in this study, the largest series reported to date, consisted of diabetic patients attending

Table 3. Results of logistic regression analysis

Variable	Parameter estimate	Standard error	Wald- χ^2	p-value
Intercept (a)	-4.560	0.154	872.0	0.001
Diabetes type	0.085	0.079	1.2	0.28
Diabetes duration	0.044	0.003	174.1	0.001
Age	0.054	0.003	436.5	0.001
Sex	-0.095	0.061	2.4	0.12

model: $\log(P/1-P) = a + \beta_1 \text{ type} + \beta_2 \text{ duration} + \beta_3 \text{ age} + \beta_4 \text{ sex}$
 (p , probability of having neuropathy)

routine hospital out-patient diabetes clinics in the UK and the prevalence of 28.5% may be an overestimate of the prevalence in the population of diabetic patients in general because patients with active complications may be more likely to be attending these clinics.

Franklin et al. [3] stated that the neurological techniques and prevalence of peripheral neuropathy are specific to the population tested. Although the prevalence reported in this study is therefore specific to the UK hospital clinic population, it is similar to that seen in other studies using equivalent methods. In the San Luis Valley study [3] a prevalence of 25.8% was found in 279 Type 2 diabetic patients whereas 34% was reported in the 400 patients assessed in the Pittsburgh epidemiology study [6]. This compares with a prevalence of 10.7% in a study looking at symptomatic neuropathy only, but also applying rigorous criteria, including neurophysiological testing [7], and 14% in the study of Knuiman et al. [8] which used diminution of pin-prick sensation alone as its diagnostic test.

The equal prevalence of diabetic peripheral neuropathy in both men and women found in this study is in contrast with the male predominance of neuropathy found in both the cross-sectional study of Franklin et al. [3] and Pirart's longitudinal follow-up of 4400 diabetic patients over 26 years [2]. However, in Pirart's study neuropathic symptoms were not used to determine the prevalence of neuropathy and also mononeuropathies were included in the overall prevalence rate. The increasing prevalence of diabetic peripheral neuropathy with duration of diabetes is in keeping with other diabetic population studies which have examined this question [2, 3, 6, 8]. The relationship with duration was independent of that with age, which also significantly, and independently, correlated with an increase in the prevalence of diabetic peripheral neuropathy.

Previous studies have either examined all patients irrespective of diabetes type [1, 2, 6, 8] or have concentrated on a specific group, Type 1 diabetic patients [4], Type 2 diabetic patients [3, 5] or a specific treatment group [9]. Due to the different methodologies involved it has been difficult to draw conclusions about the prevalence of diabetic neuropathy according to diabetes type. In this study the overall prevalence of diabetic peripheral neuropathy in Type 2 diabetic patients was significantly higher than that in Type 1 diabetic patients. Even after correcting for the Type 2 diabetic patients being older this difference persisted. This trend was maintained throughout the range of known duration of diabetes and may represent the long prodromal period between the

onset and diagnosis of Type 2 diabetes [22] or may reflect a true difference in the underlying pathology.

The most important reason for assessing the prevalence of diabetic neuropathy is to assess the risk of neuropathic foot ulceration [23]. When all of the associations, between diabetes type, age and duration are considered, the prevalence of diabetic peripheral neuropathy in Type 2 diabetic patients aged over 60 years and attending the hospital clinic is greater than 50% and the need for regular examination of the feet, proper footcare and appropriate education for these patients cannot therefore be stressed too often.

Acknowledgements. We would like to thank Wyeth Laboratories for their support of this study and H. Shaikhani and D. Shaw for performing the statistical analysis. We would also like to thank the investigators in every centre for their time and effort in completing the study.

References

1. Goodman JL, Baumoeel S, Frankel L, Marcus LJ, Wasserman S (1953) The diabetic neuropathies. CC Thomas Springfield, Illinois, pp 1-66
2. Pirart J (1979) Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed between 1947 and 1973. *Diabetes Care* 1: 168-188
3. Franklin GM, Kahn LB, Bacter J, Marshall JA, Hamman RF (1990) Sensory neuropathy in non-insulin dependent diabetes mellitus. The San Luis Valley study. *Amer J Epidemiol* 131: 633-643
4. The DCCT Research Group (1988) Factors in the development of diabetic neuropathy. *Diabetes* 37: 476-481
5. Lehtinen JM, Uusitupa M, Siitonen O, Pyörälä K (1989) Prevalence of neuropathy in newly diagnosed NIDDM and non-diabetic control subjects. *Diabetes* 38: 1307-1313
6. Maser RE, Steenkiste AR, Dorman JS et al. (1989) Epidemiological correlates of diabetic neuropathy: report from Pittsburgh epidemiology of diabetes complications study. *Diabetes* 38: 1456-1461
7. Boulton AJM, Knight G, Drury J, Ward JD (1985) The prevalence of symptomatic, diabetic neuropathy in an insulin-treated population. *Diabetes Care* 8: 125-128
8. Knuiman MW, Welborn TA, McCann VJ, Stanton KG, Constable IJ (1986) Prevalence of diabetic complications in relation to risk factors. *Diabetes* 35: 1332-1339
9. Fry IK, Hardwick C, Scott GW (1962) Diabetic neuropathy: a survey and follow-up of 66 cases. *Guys Hosp Rep* 111: 113-129
10. Newrick PG, Boulton AJM, Ward JD (1986) The distribution of diabetic neuropathy in a British clinic population. *Diabetes Res Clin Prac* 2: 263-268
11. Neil HAW, Thompson AV, Thorogood M, Fowler GH, Mann JI (1989) Diabetes in the elderly: the Oxford community diabetes study. *Diabetic Med* 6: 608-613
12. Dyck PJ, Karnes JL, Daube J, O'Brien P, Service FJ (1985) Clinical and neuropathologic criteria for the diagnosis and staging of diabetic polyneuropathy. *Brain* 108: 861-880
13. Dyck PJ (1988) Detection, characterization and staging of polyneuropathy assessed in diabetics. *Muscle Nerve* 11: 21-32
14. Melzack R (1984) The McGill pain questionnaire. In: Bromm P (ed) Pain measurement in man. Neurophysiological correlates of pain. Elsevier Scientific Publishers, Amsterdam pp 327-348
15. Masson EA, Gem J, Hunt L, Boulton AJM (1989) A novel approach to the diagnosis and assessment of symptomatic diabetic neuropathy. *Pain* 38: 25-28
16. Dyck PJ, Kratz KM, Lehman KA et al. (1991) The Rochester diabetic neuropathy study: design, criteria for types of neurop-

- athy, selection bias, and reproducibility of neuropathic tests. *Neurology* 41: 799–807
17. Steiness IB (1957) Vibratory perception in diabetics. *Acta Medica Scand* 158: 327–355
 18. Bertlesmann FW, Heimans JJ, Weber EJM, van der Veen EA, Schouten JA (1985) Thermal discrimination thresholds in normal subjects and in patients with diabetic neuropathy. *J Neurol Neurosurg Psychiatry* 48: 685–690
 19. Masson EA, Veves A, Fernando D, Boulton AJM (1989) Current perception thresholds: a new, quick and reproducible method for the assessment of peripheral neuropathy in diabetes mellitus. *Diabetologia* 32: 724–728
 20. Consensus Statement (1988) Report and recommendations of the San Antonio conference on diabetic neuropathy. *Diabetes* 37: 1000–1004
 21. Mayne N (1965) Neuropathy in the diabetic and non-diabetic populations. *Lancet* II: 1313–1316
 22. Jarrett RJ, McCartney P, Keen H (1982) The Bedford survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics. *Diabetologia* 22: 79–84
 23. Boulton AJM (1990) The diabetic foot – neuropathic in origin? RD Lawrence Lecture. *Diabetic Med* 7: 852–858

Received: 15 May 1992 and in revised form: 12 October 1992

Dr. A. J. M. Boulton
University Dept of Medicine
Manchester Royal Infirmary
Oxford Road
Manchester M13 9WL
UK